1255040-87-9

Upstream product

• 1402586-55-3 C₁₄H₁₄ClN₃ 
• 1402586-36-0 methyl 2-(3-fluoro-4-(methylsulfonyl)phenyl)propanoate 
• 82560-12-1 3-tert-butyl-1H-pyrazole-5-amine 
• 1402586-35-9 methyl 2-(3-fluoro-4-(methylthio)phenyl)propanoate 
• 1402586-34-8 2-(3-fluoro-4-(methylthio)phenyl)propanoic acid 
• 259543-76-5 2-(3-fluoro-4-(methylthio)phenyl)acetic acid 
• 1402586-33-7 2-(3-fluoro-4-(methylthio)phenyl)-2-oxoacetic acid 
• 1402586-32-6 ethyl 2-(3-fluoro-4-(methylthio)phenyl)-2-oxoacetate 
• 655-20-9 2-fluorothioanisole 
• 2557-78-0 2-fluorothiophenol 
• 59997-51-2 trimethylacetylacetonitrile 
• 598-98-1 Methyl pivalate 
• 3282-30-2 pivaloyl chloride 
• 1254713-63-7 (3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methanamine 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN SO2-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a S02-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.